[A18-14] Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 16.08.2018
Commission awarded on 20.02.2018 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Patients with active psoriatic arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies
Patients who have responded inadequately to treatment with a conventional DMARD or a bDMARD: added benefit not proven due to lack of data. If first bDMARD treatment is indicated: hint of minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-47||Ixekizumab (psoriatic arthritis) - Addendum to Commission A18-14||Commission completed|
|A17-07||Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-65||Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A20-66||Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V||Commission completed|